A must-attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.
Our conference has been designed around three core market access areas, each with a specific mission to bring you the latest insights and information for accelerating patient access.
Developments in strategy and HTA
- The importance of patient engagement throughout the HTA process
- Using patient registries in HTAs
- Appraisal process of medical devices compared with drugs
- Health economic modelling of digital apps
- Access to Orphan Medicines: Developing policies for the future
Innovation tools
- Approaches to utilising Real World Evidence (RWE)
- Using analytics and big data to gain competitive advantage in Market Access
- Collaborative working and horizon scanning
- Harnessing digital systems and technology to find new levels of patient value
Pricing and policy
- VPAS – what you need to know
- Updates on The Commercial Framework
- Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
- The NHS Long Term Plan and what this actually means for pharma companies
Who should attend?
This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.
The job functions that will benefit most include:
- Heads of Market Access
- Country Managers
- Health Economists
- Commercial Directors
- Marketing Directors
- Managing Directors
- Chief Executives
- Medical Directors
- Policy Officers/Executives
- Policy Advisors
Speakers
Lindsay Weaver – CEO, Metabolic Support UK
The importance of patient engagement throughout the HTA process
David Gillen – Vice President international Medical Affairs, Vertex
Using patient registries in HTAs
Melinda Goodall – Associate Director, NICE
Andi Orlowski – Head of Business Intelligence, Imperial College Healthcare Partners
Approaches to utilising Real World Evidence (RWE)
David Watson – Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)
The Voluntary Scheme; what you need to know
Darren Spevick – Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group
Harnessing digital systems and technology to find new levels of patient value
Carla Deakin – Programme Director, Commercial & Managed Access, NICE
Sarah Walker – Senior Consultant Policy and Public Affairs, MAP BioPharma
Kate Learoyd – Campaign Manager, NSPKU – National Society for Phenylketonuria
Christian Hill – CEO, MAP BioPharma
